<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antithrombotic therapy post-TAVI</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antithrombotic therapy post-TAVI</h1>
<div class="graphic"><div class="figure"><div class="ttl">Antithrombotic therapy post-TAVI</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">Refer to UpToDate content on indications for anticoagulation.</div><div class="graphic_footnotes">TAVI: transcatheter aortic valve implantation; DAPT: dual antiplatelet therapy; SAPT: single antiplatelet therapy; VKA: vitamin K antagonist; DOAC: direct oral anticoagulant.<br/><br/>* Therapeutic anticoagulation does not include low-dose heparin therapy for prophylaxis against venous thromboembolic disease. The most common concurrent indication for therapeutic anticoagulation post-TAVI is atrial fibrillation with risk factors favoring anticoagulation (eg, CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥2). The choice and duration of anticoagulant therapy is based upon the indication for anticoagulation.<br/>¶ Common indications for DAPT include recent coronary stent implantation and recent acute coronary syndrome.<br/>Δ The choice and duration of antiplatelet and anticoagulant therapy are based upon the indications for these agents. Long-term triple antithrombotic therapy (dual antiplatelet therapy plus anticoagulation) is generally avoided given evidence suggesting worse outcomes compared with dual antithrombotic therapy.<br/><font class="lozenge">◊</font> When a patient no longer requires anticoagulation or DAPT, then SAPT is used.<br/>§ Antiplatelet therapy is not required in this setting. During the first 3 months post-TAVI, VKA is the preferred anticoagulant. After the first 3 months, the choice of anticoagulant (VKA or DOAC) is based upon the indication for anticoagulation and other clinical factors. <br/>¥ DAPT consists of aspirin 75 to 100 mg daily plus clopidogrel 75 mg daily. No loading dose is required for aspirin therapy. Clopidogrel is initiated as a 300 mg loading dose followed by a 75 mg daily maintenance dose.<br/>‡ In this setting, SAPT is generally aspirin 75 to 100 mg daily. If aspirin is contraindicated due to hypersensitivity, clopidogrel is an alternative.<br/>† A reasonable alternative is to use DAPT in the intermediate term (during the initial 3 to 6 months depending upon valve type) followed by lifelong SAPT, which is the approach used in the pivotal TAVI trials. If intermediate-term DAPT is chosen, it is continued for the first 6 months (for the SAPIEN valve) or for the first 3 months (for the Evolut R/PRO/PRO-PLUS valve).</div><div id="graphicVersion">Graphic 128310 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
